BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 21493182)

  • 1. RANKL inhibition: a promising novel strategy for breast cancer treatment.
    González-Suárez E
    Clin Transl Oncol; 2011 Apr; 13(4):222-8. PubMed ID: 21493182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis.
    Gonzalez-Suarez E; Jacob AP; Jones J; Miller R; Roudier-Meyer MP; Erwert R; Pinkas J; Branstetter D; Dougall WC
    Nature; 2010 Nov; 468(7320):103-7. PubMed ID: 20881963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling.
    Tan W; Zhang W; Strasner A; Grivennikov S; Cheng JQ; Hoffman RM; Karin M
    Nature; 2011 Feb; 470(7335):548-53. PubMed ID: 21326202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the RANK/RANKL pathway in breast cancer.
    Kiesel L; Kohl A
    Maturitas; 2016 Apr; 86():10-6. PubMed ID: 26921922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.
    Infante M; Fabi A; Cognetti F; Gorini S; Caprio M; Fabbri A
    J Exp Clin Cancer Res; 2019 Jan; 38(1):12. PubMed ID: 30621730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.
    Dougall WC
    Clin Cancer Res; 2012 Jan; 18(2):326-35. PubMed ID: 22031096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RANKL/RANK: from bone loss to the prevention of breast cancer.
    Sigl V; Jones LP; Penninger JM
    Open Biol; 2016 Nov; 6(11):. PubMed ID: 27881737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bone metastasis and RANKL].
    Nakashima T
    Clin Calcium; 2014 Aug; 24(8):1201-8. PubMed ID: 25065872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RANKL/RANK control Brca1 mutation- .
    Sigl V; Owusu-Boaitey K; Joshi PA; Kavirayani A; Wirnsberger G; Novatchkova M; Kozieradzki I; Schramek D; Edokobi N; Hersl J; Sampson A; Odai-Afotey A; Lazaro C; Gonzalez-Suarez E; Pujana MA; Cimba F; Heyn H; Vidal E; Cruickshank J; Berman H; Sarao R; Ticevic M; Uribesalgo I; Tortola L; Rao S; Tan Y; Pfeiler G; Lee EY; Bago-Horvath Z; Kenner L; Popper H; Singer C; Khokha R; Jones LP; Penninger JM
    Cell Res; 2016 Jul; 26(7):761-74. PubMed ID: 27241552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RANKL/RANK-beyond bones.
    Hanada R; Hanada T; Sigl V; Schramek D; Penninger JM
    J Mol Med (Berl); 2011 Jul; 89(7):647-56. PubMed ID: 21445556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.
    Nolan E; Vaillant F; Branstetter D; Pal B; Giner G; Whitehead L; Lok SW; Mann GB; ; Rohrbach K; Huang LY; Soriano R; Smyth GK; Dougall WC; Visvader JE; Lindeman GJ
    Nat Med; 2016 Aug; 22(8):933-9. PubMed ID: 27322743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis.
    Schramek D; Sigl V; Penninger JM
    Trends Endocrinol Metab; 2011 May; 22(5):188-94. PubMed ID: 21470874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Roadmap of RANKL/RANK Pathway in Cancer.
    Casimiro S; Vilhais G; Gomes I; Costa L
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of the RANKL/RANK Axis in the Prevention and Treatment of Breast Cancer with Immune Checkpoint Inhibitors and Anti-RANKL.
    Simatou A; Sarantis P; Koustas E; Papavassiliou AG; Karamouzis MV
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review.
    de Groot AF; Appelman-Dijkstra NM; van der Burg SH; Kroep JR
    Cancer Treat Rev; 2018 Jan; 62():18-28. PubMed ID: 29154022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can we prevent BRCA1-associated breast cancer by RANKL inhibition?
    Kotsopoulos J; Singer C; Narod SA
    Breast Cancer Res Treat; 2017 Jan; 161(1):11-16. PubMed ID: 27783278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini.
    Gonzalez-Suarez E; Branstetter D; Armstrong A; Dinh H; Blumberg H; Dougall WC
    Mol Cell Biol; 2007 Feb; 27(4):1442-54. PubMed ID: 17145767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
    Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
    Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RANK as a therapeutic target in cancer.
    González-Suárez E; Sanz-Moreno A
    FEBS J; 2016 Jun; 283(11):2018-33. PubMed ID: 26749530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RANKLed by the Complexity of Signaling in Breast Cancer Metastasis to the Brain.
    Wang K; Hackney JR; Siegal GP; Wei S
    Clin Breast Cancer; 2020 Oct; 20(5):e569-e575. PubMed ID: 32381383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.